Abstract-Isoprostanes are endogenously formed end products of lipid peroxidation. Furthermore, they are markers of oxidative stress and independent risk markers of coronary heart disease. In patients experiencing coronary heart disease, impaired angiogenesis may exacerbate insufficient blood supply of ischemic myocardium. We therefore hypothesized that isoprostanes may exert detrimental cardiovascular effects by inhibiting angiogenesis. We studied the effect of isoprostanes on vascular endothelial growth factor (VEGF)-induced migration and tube formation of human endothelial cells (ECs), and cardiac angiogenesis in vitro as well as on VEGF-induced angiogenesis in the chorioallantoic membrane assay in vivo. The isoprostanes 8-iso-PGF 2␣ , 8-iso-PGE 2 , and 8-iso-PGA 2 inhibited VEGF-induced migration, tube formation of ECs, and cardiac angiogenesis in vitro, as well as VEGF-induced angiogenesis in vivo via activation of the thromboxane A 2 receptor (TBXA2R): the specific TBXA2R antagonists SQ-29548, BM 567, and ICI 192,605 but not the thromboxane A 2 synthase inhibitor ozagrel blocked the effect of isoprostanes. The isoprostane 8-iso-PGA 2 degraded into 2 biologically active derivatives in vitro, which also inhibited EC tube formation via the TBXA2R. Moreover, short hairpin RNA-mediated knockdown of the TBXA2R antagonized isoprostane-induced effects. In addition, Rho kinase inhibitor Y-27632 reversed the inhibitory effect of isoprostanes and the thromboxane A 2 mimetic U-46619 on EC migration and tube formation. Finally, the various isoprostanes exerted a synergistic inhibitory effect on EC tube formation. We demonstrate for the first time that isoprostanes inhibit angiogenesis via activation of the TBXA2R. By this mechanism, isoprostanes may contribute directly to exacerbation of coronary heart disease and to capillary rarefaction in disease states of increased oxidative stress.
O xidative stress is characterized by an imbalance between increased exposure to reactive (oxygen) species, predominantly free radicals, and antioxidant defense mechanisms. Endogenously, such free radicals are generated by enzymatic sources such as the NADPH oxidase or derive from mitochondria, eg, in the pathophysiological state of tissue hypoxia. 1, 2 Free radicals cause direct harm to essential cellular components, such as DNA, lipids, and proteins. 2 As 1 example, free radical-induced peroxidation of arachidonic acid leads to cyclooxygenase-independent in vivo formation of prostaglandin-like substances, named isoprostanes. 3 Hence, endogenous formation of isoprostanes should mirror the exposure of an organism to free radicals. In line with this consideration, a growing body of evidence clearly underlines the validity of isoprostanes as in vivo markers of oxidative stress. 4 Most interestingly, patients with established coronary heart disease (CHD) but also patients at high cardiovascular risk, eg, smokers, hypercholesterolemic, diabetic, and obese patients or patients with salt-sensitive or renovascular hypertension, exhibit elevated urinary or plasmatic concentrations of isoprostanes. 4 -11 Moreover, recently published experimental data suggest that isoprostanoids strongly accumulate in hypoxic myocardium. 12 In addition, we lately identified isoprostanes as independent risk markers of CHD. 5 Hence, our findings point to a more direct role isoprostanes in cardiovascular pathophysiology. Indeed, a plethora of experimental evidence demonstrate that isoprostanes are biologically active compounds. 13 For instance, isoprostanes have been shown to induce vasoconstriction via the thromboxane A 2 receptor (TBXA2R) and may promote the formation of atherosclerotic plaques in ApoE knockout mice via the same receptor. 14, 15 Taking into account the short half life of thromboxane A 2 in vivo (approximately 30 seconds), isoprostanes may represent important stable ligands of the TBXA2R, especially in pathophysiological states of increased oxidative stress. 16 Thus, isoprostanes may attract attention not only as valid markers of oxidative stress in vivo but also as mediators of cardiovascular pathology. In this regard, vascular remodelling has been shown to occur in the chronically hypoxic heart of patients with CHD and may be of major importance to maintain cardiac blood flow in these patients. 17, 18 Moreover, several groups have demonstrated that patients at high cardiovascular risk, eg, hypertensive individuals, or patients with established CHD exhibit an impaired response to angiogenic stimuli and a rarefaction of the peripheral microvascular (capillary) bed. 19, 20 Because recent experimental findings have indicated that synthetic TBXA2R mimetics may inhibit crucial steps of the angiogenesis, eg, the sprouting of new vessels from preexisting vessels, 21, 22 we hypothesized that isoprostanes may contribute to vascular rarefaction by inhibiting angiogenesis via activation of the TBXA2R.
The data presented herein provide evidence that isoprostanes inhibit vascular endothelial growth factor (VEGF)-induced endothelial cell migration, tube formation, and cardiac angiogenesis in vitro, as well as angiogenesis in vivo, via activation of the TBXA2R.
Materials and Methods
Several methods, such as assessment of endothelial cell migration, the cardiac angiogenesis assay, and the chorioallantoic membrane (CAM) angiogenesis assay, have been described previously. [23] [24] [25] [26] An expanded Materials and Methods section is available in the online data supplement at http://circres.ahajournals.org. 2␣ affects basal migration in a biphasic fashion. TBXA2R antagonist SQ-29548 abolishes both the stimulatory and inhibitory effect of 8-iso-PGF 2␣ on basal HDMEC migration. B, 8-Iso-PGF 2␣ concentration-dependently inhibits VEGF-induced HDMEC migration. TBXA2R antagonist SQ-29548 reverses the 8-iso-PGF 2␣ -induced inhibitory effect. Results are expressed as meansϮSD of 2 separate experiments performed at least in triplicate (nϭ8 to 12).*PϽ0.01 vs vehicle, $PϽ0.01 vs VEGF, **PϽ0.01 vs VEGF plus 8-iso-PGF 2␣ . Rho kinase inhibitor Y-27632 (10 Ϫ5 mol/L) almost completely reverses the inhibitory effect of 8-iso-PGF 2␣ (3ϫ10 Ϫ5 mol/L) and U-46119 (3ϫ10 Ϫ5 mol/L) on basal (C) and VEGFinduced (50 ng/mL) (D) HDMEC migration. Results are expressed as meansϮSD of 2 separate experiments performed at least in triplicate (nϭ6 to 12). §PϽ0.01 vs control, **PϽ0.01 vs 8-iso-PGF 2␣ /U-46119; *PϽ0.001 vs control; $PϽ0.001 vs VEGF; #PϽ0.001 vs VEGFϩ8-iso-PGF 2␣ /U-46119.
Results

Influence of 8-Iso-PGF 2␣ and Thromboxane A 2 Mimetic U-46119 on Basal Migration of Endothelial Cells
To explore the effect of isoprostanes on basal migration of endothelial cells, we performed transwell migration assays using increasing concentrations of 8-iso-PGF 2␣ . As shown in Figure 1A, Because under in vivo conditions, VEGF plays a dominant role in the process of angiogenesis, we subsequently examined the effect of isoprostanes on VEGF-induced endothelial cell migration. HDMECs were subjected to transwell migration assays and incubated with VEGF (50 ng/mL) in the presence of increasing concentrations of 8-iso-PGF 2␣ ( Figure  1B Figure 2A ). Moreover, the inhibitory effect was almost completely reversed by the TBXA2R antagonist SQ-29548 ( Figures 1B and 2A) . SQ-29548 itself had no significant effect on basal or VEGF-induced migration of HDMECs or HCAECs (data not shown). Moreover, the inhibitory effects of 8-iso-PGF 2␣ and U-46119 were not attributable to cytotoxic effects in HDMECs ( Figure 2B ). However, 8-iso-PGF 2a marginally but significantly induced apoptosis of HCAECs treated with 50 ng/mL VEGF as compared to those treated with VEGF alone (15.7Ϯ1.3% versus 11.9Ϯ1.3%; PϽ0.05; nϭ8/8), an effect that was, again, partially reversed by the TBXA2R antagonist SQ-29548 (13.3Ϯ1.4%). Knockdown of TBXA2R by lentiviral short hairpin RNA selectively abolished the inhibitory effect of 8-iso-PGF 2␣ on VEGF-induced migration of endothelial cells, whereas transduction with scrambled short hairpin RNA had no effect ( Figure IA in the online data supplement). The efficacy of lentiviral knockdown was confirmed by quantitative PCR and Western blot analysis (supplemental Figures IC and ID) . To investigate whether isoprostanemediated inhibition of VEGF-induced migration was caused by isoprostane-induced production of thromboxane A 2 , we repeated the experiments after preincubation and in presence of the specific thromboxane A 2 synthase inhibitor ozagrel (3ϫ10 Ϫ5 mol/L). However, ozagrel did not alter the inhibitory effect of isoprostanes (8-iso-PGF 2␣ and 8-iso-PGA 2 ) on VEGF-induced HDMEC migration (data not shown). Because activation of Rho kinase was shown to play a key role in the 8-iso-PGF 2␣ -mediated inhibition of basal EC migration, we also investigated the effect of the Rho kinase inhibitor Y-27632 on isoprostane-mediated inhibition of VEGF-induced HDMEC migration ( Figure 1D ). Again Y-27632 strongly attenuated the inhibitory effect of 8-iso- PGF 2␣ and U-46119 on VEGF-induced HDMEC migration, thereby indicating that VEGF-induced migration depends on a concerted activation of Rho kinase. In contrast, Y-27632 itself had no effect on basal or VEGF-stimulated endothelial cell migration (supplemental Figure IIIB) . Figure 3C ). This inhibitory effect was again resolved by the TBXA2R antagonist SQ-29548, short hairpin RNA-mediated knockdown of TBXA2R, and the Rho kinase inhibitor Y-27632 (supplemental Figures IA and IIIB) . Moreover, simultaneous addition of 8-iso-PGF 2␣ , 8-iso-PGA 2 , and 8-iso-PGE 2 (3ϫ10 Ϫ5 mol/L, respectively) resulted in a significantly stronger inhibition of endothelial cell tube formation compared with the inhibition induced by any of the isoprostanes alone (54Ϯ9%; PϽ0.01 versus 8-iso-PGF 2␣ , 8-iso-PGA 2 , 8-iso-PGE 2 alone) indicating a synergistic inhibitory effect of isoprostanes on tube formation of endothelial cells in vitro.
Influence of 8-
Decomposition of the Isoprostane 8-Iso-PGA 2 Into Two Biologically Active Compounds, X and Y, In Vitro
In contrast to the isoprostane 8-iso-PGF 2␣ , which has been shown to be chemically stable, the stability of further isoprostanes, such as 8-iso-PGA 2 , remained elusive. Hence, we investigated the stability of 8-iso-PGA 2 under "physiological" conditions (pH 7.4, 37°C) in vitro ( Figure  4A through 4C ). Most interestingly, we observed a decomposition of 8-iso-PGA 2 within 24 hours into an unknown compound, termed X, which, again, completely transformed within 24 Figure 4H . To test biological activity of both compounds, the effect on Figure 4D ). These findings strongly suggest that specific instable isoprostanes may nonenzymatically form biologically active derivatives in vivo, which may exert synergistic effects together with further endogenous isoprostanes via the TBXA2R.
Effect of 8-Iso-PGF 2␣ and U-46119 on Cardiac Angiogenesis In Vitro
To further elucidate the role of 8-iso-PGF 2␣ and U-46119 in the process of angiogenesis, we chose an experimental that which is more closely related to the in vivo situation ( Figure 6 ). Interestingly, both 8-iso-PGF 2␣ and U-46119 (at 3ϫ10 Ϫ5 mol/L, respectively) attenuated hypoxia-driven VEGF and platelet-derived growth factor (PDGF)-induced cardiac angiogenesis in vitro ( Figure 6C and 6D) . Again, this inhibitory effect of both compounds was almost completely reversed by the TBXA2R antagonist SQ-29548 ( Figure 6E and 6F) . In contrast, low concentrations of 8-iso-PGF 2␣ applied in the absence of VEGF and PDGF did not affect hypoxia-driven cardiac angiogenesis in our in vitro system (data not shown).
Effect of 8-Iso-PGF 2␣ and U-46119 on VEGF-Induced Angiogenesis in the CAM Assay In Vivo
The CAM assay was chosen to elucidate the effect of 8-iso-PGF 2␣ on VEGF-induced angiogenesis in vivo. In comparison to the control, in which only PBS was added, the application of VEGF induced a strong vascularization as it is recognizable by the intense vascular branching under the mesh ( Figure 5 ). In contrast, the simultaneous application of VEGF and 8-iso-PGF 2␣ or the thromboxane A 2 mimetic U-46619 blocked the VEGF-induced neovascularization. The combined application of VEGF and the specific TBXA2R antagonists SQ-29548 did not alter the angiogenic effect of VEGF. The inhibitory effect of 8-iso-PGF 2␣ was partially reversed when VEGF and 8-iso-PGF 2␣ were applied simultaneously with SQ-29548. Similar effects were observed in the case of combined application of VEGF in presence of U-46619 and SQ-29548.
Effect of 8-Iso-PGF 2␣ on Basal and VEGF-Induced Akt and Extracellular Signal-Regulated Kinase and Focal Adhesion Kinase Signaling in HDMECs
As Akt has been shown to affect endothelial cell motility, we investigated the effect of 8-iso-PGF 2␣ on basal as well as VEGF-induced Akt (Ser-473) phosphorylation in HDMECs. Interestingly, lower promigratory concentrations of 8-iso-PGF 2␣ (10 Ϫ7 mol/L) induced basal phosphorylation of Akt ( Figure 7A ). Again, TBXA2R antagonist SQ-29548, which abolished the promigratory effect of low-concentrated 8-iso-PGF 2␣ , also reversed the 8-iso-PGF 2␣ -induced Akt phosphorylation ( Figure  7A ). Moreover, HDMECs treated with high (antimigratory) concentrations of 8-iso-PGF 2␣ (3ϫ10 Ϫ5 mol/L) exhibited levels of phosphorylated Akt comparable to those of unstimulated control cells ( Figure 7A ). In contrast, extracellular signalregulated kinase (ERK)-1/-2 (Thr202/Tyr204) phosphorylation, dose-dependently increased in HDMECs treated with 8-iso-PGF 2␣ , an effect that was sensitive to the TBXA2R antagonist SQ-29548 ( Figure 7A ). However, 8-iso-PGF 2␣ did not significantly affect VEGF-induced Akt, ERK, or focal adhesion kinase (FAK) (pY397) phosphorylation after 15 minutes of costimulation ( Figure 7B ; p-FAK data not shown).
Effect of 8-Iso-PGF2 ␣ on Endothelial Cell Apoptosis
To investigate the effect of 8-iso-PGF 2a on endothelial cell apoptosis, we flow-cytometrically assessed annexin V-fluorescein isothiocyanate (FITC) binding to stimulated HCAECs. After 12 hours slightly in this setting, 8-iso-PGF 2␣ but significantly induced apoptosis of HCAECs treated with VEGF (50 ng/mL; Figure 2C and 2D) as compared to those treated with VEGF alone (15.7Ϯ1.3% versus 11.9Ϯ1.3%; PϽ0.05; nϭ8/8), an effect that was, again, partially reversed by the TBXA2R antagonist SQ-29548 (13.3Ϯ1.4%).
Effect of 8-Iso-PGF 2␣ and U-46119 on Generation of F-Actin Stress Fibers in HDMECs
Stress fiber formation, which is critical for endothelial cell movement, has been shown to be regulated by a concerted activation of Rho kinase. 27 Thus, we investigated the influence of 8-iso-PGF 2␣ and U-46119 on generation of F-actin stress fibers in HDMECs. HDMECs treated with VEGF (50 ng/mL, 4 hour; Figure 8B ) showed increased formation of stress fibers as compared with untreated HDMECs ( Figure  8A ). 8-Iso-PGF 2␣ and U-46119 (3ϫ10 Ϫ5 mol/L, respectively) interfered with the VEGF-induced effects and induced a nondirectional stress fiber formation and focal adhesion pattern ( Figure 8C and 8E) . This effect could be reversed by concomitant stimulation with SQ-29548 ( Figure 8D and 8F) .
Discussion
The main novel findings of the present study are that isoprostanes concentration-dependently inhibit VEGF-induced migration and tube formation of endothelial cells as well as VEGFinduced cardiac angiogenesis in vitro and angiogenesis in vivo via activation of the TBXA2R. In this regard, different isoprostanes exerted a synergistic inhibitory effect on endothelial cell tube formation. Moreover, spontaneously formed derivatives of 8-iso-PGA 2 , termed compound X and Y, were biologically active and inhibited in vitro tube formation of HCAECs. Furthermore, the inhibitory effect of isoprostanes on VEGF-induced angiogenesis was sensitive to pharmacological inhibition of Rho kinases, thereby indicating involvement of Rho kinases in the antiangiogenic effect of isoprostanes.
Angiogenesis, the formation of new blood capillaries, is of crucial importance for the pathophysiology of multiple diseases, including myocardial ischemia in patients with CHD. 19 The growth of neovessels is a tightly regulated process that is controlled by the concerted release of pro-and antiangiogenic factors. 19 VEGF has emerged as the key regulator of angiogenesis and promotes most of the critical steps of this process, such as endothelial cell movement, proliferation, and capillary tube formation. 28 Most interestingly, VEGF is elevated in the serum of patients with myocardial ischemia and may stimulate neovascularization of the ischemic myocardium and promote the development of collateral vessels to restore or maintain myocardial blood flow. 17, 18 Hence, antiangiogenic stimuli counteracting VEGF-induced revascularization processes may negatively affect these essential hypoxia-driven adaptive changes. In the present study, we clearly demonstrate that isoprostanes, endogenously formed end products of free radical-induced lipid peroxidation, inhibit VEGFinduced migration and tube formation of ECs, as well as cardiac angiogenesis in vitro and angiogenesis in vivo. In this regard, findings of our group (and others) that isoprostanes accumulate in patients with CHD and in patients at high cardiovascular risk, eg, hypertensive individuals, clearly underline the clinical importance of our experimental findings. Moreover, recently published data demonstrate that isoketals, which form nonenzymatically from the same precursors (H 2 -isoprostane regioisomers) in vivo as the 8-isoprostanes investigated in our study, considerably accumulate in hypoxic myocardium. 12 These findings strongly suggest that elevated systemic concentrations of isoprostanes observed in patients Figure 5 . 8-Iso-PGF 2␣ and U-46119 both inhibit VEGFinduced angiogenesis in the CAM assay in vivo via activation of the TBXA2R. In comparison to control (A), the application of VEGF (50 ng/mL) (B) induced a strong vascularization because it is recognizable by the intense vascular branching under the mesh. In contrast, the simultaneous application of VEGF and 8-iso-PGF 2␣ (C) or the thromboxane A 2 mimetic U-46619 (3ϫ10 Ϫ5 mol/L, respectively) (E) blocked VEGF-induced neovascularization. The inhibitory effect of 8-iso-PGF 2␣ was partially reversed when VEGF and 8-iso-PGF 2␣ were applied simultaneously with SQ-29548 (3ϫ10 Ϫ5 mol/L) (D). Similar effects were observed in the case of combined application of VEGF in presence of U-46619 and SQ-29548 (F). In contrast, the combined application of VEGF and the specific TBXA2R antagonists SQ-29548 (G) did not alter the angiogenic effect of VEGF.
with CHD (stable CHD patients display a 2-to 3-fold increase in systemic isoprostane concentrations, which are in the concentration range of 30 to 40 ng/L in the plasma of healthy humans 29 ) may not adequately reflect enhanced local generation of isoprostanes in hypoxic tissues. Moreover, isoprostane metabolites and so far unknown but biologically active decomposition products of specific isoprostanes (eg, cyclopentenone isoprostane derivatives X and Y), which are not captured in the present analytic routines for isoprostane detection, may accumulate in patients at high cardiovascular risk and synergistically exert antiangiogenic effects (as shown in this study for the isoprostanes 8-iso-PGF 2␣ , 8-iso-PGA 2 , and 8-iso-PGE 2 ). Hence, isoprostanes may contribute to development of capillary rarefaction, which has been observed in pathophysiological states of increased oxidative stress, such as CHD or systemic hypertension. 19, 20 In our study, 8-iso-PGF 2␣ , 8-iso-PGA 2 , and 8-iso-PGE 2 inhibited the VEGF-induced angiogenic response via activation of the TBXA2R, because the TBXA2R antagonists SQ-29548, BM 567, and ICI 192,605 reversed isoprostaneinduced inhibition of angiogenesis (online data supplement). Besides pharmacological antagonism of the TBXA2R, we were able to demonstrate that lentiviral knockdown of TBXA2R also resolved the inhibitory effect of 8-iso-PGF 2␣ (online data supplement). Our findings are in line with other studies that demonstrate antiangiogenic actions of this receptor, 21 ,22,30 although 1 group described proangiogenic effects of TBXA2R activation. 31 The present study identifies for the first time isoprostanes as important endogenous compounds, which are capable of exerting antiangiogenic effects via activation of the TBXA2R. Moreover, isoprostanes slightly but significantly induced apoptosis in endothelial cells via activation of the TBXA2R, an effect that may partially contribute to the antiangiogenic properties of the compounds. Previously, a proapoptotic effect of isoprostanes on neuromi- crovascular endothelial cells has been described. 32 In addition to their antiangiogenic actions, isoprostanes may, by this mechanism, contribute to endothelial dysfunction in disease states of increased oxidative stress. 33 In contrast to the findings of previous publications, 21,22 our results do not point to an inhibitory effect of the thromboxane A 2 mimetic U-46119 or 8-iso-PGF 2␣ on VEGF-induced protein kinase B/Akt (Ser-473) or FAK (pY397) phosphorylation in endothelial cells. The reason for this discrepancy may be ascribed to different cell types studied (HDMECs versus HUVECs) but remain uncertain. Moreover, U-46119 or 8-iso-PGF 2␣ did not significantly affect VEGF-induced ERK-1/-2 phosphorylation after 15 minutes of costimulation in HDMECs. However, the inhibitory effect of 8-iso-PGF 2␣ and U-46119 was almost completely abolished by coincubation with the Rho kinase inhibitor Y-27632, thereby indicating that a pronounced and persistent TBXA2R-mediated Rho kinase activation may be responsible for the isoprostane-induced inhibition of basal and VEGF-stimulated endothelial cell migration and tube formation. This perception is supported by detection of an increased and more persistent RhoA activation induced by concomitant stimulation with 8-iso-PGF 2a in endothelial cells as compared to the observed transient RhoA activation induced by VEGF alone (online data supplement). Moreover, very recent data from Wikström et al support the notion that activation of the TBXA2R mediates a persistent activation of RhoA, which, in turn, inhibits depolymerization of F-actin. 34 In this regard, RhoA and downstream Rho kinases are known to play a crucial role in endothelial cell motility by regulating the formation of F-actin stress fibers as well as focal adhesion turnover. 35 Hence, RhoAmediated inhibition of F-actin depolymerization could disturb the concerted dynamics of F-actin reorganization, which is necessary for cell movement. Indeed, histological analysis of 8-iso-PGF 2␣ -and U-46119 -treated HDMECs revealed that these substances disturbed the directional and concerted VEGFinduced stress fiber formation and focal adhesion formation.
Moreover, new findings suggest that persistent Rho kinase activity may inhibit endothelial cell motility of endothelial cells by increasing cell adhesion to the substratum or slowing down turnover of focal adhesions. 27 In addition, Rho kinase activation may counteract angiogenesis in ischemic tissues by mediating downregulation of endothelial NO synthase. 36 8-Iso-PGF 2␣ and 8-iso-PGA 2 exerted a biphasic response on basal migration of HDMECs and HCAECs, respectively, with lower concentrations moderately inducing basal EC migration. In line with these observations, lower promigratory concentrations of 8-iso-PGF 2␣ induced basal Akt phosphorylation in HDMECs, whereas higher antimigratory concentrations did not. In contrast, ERK-1/-2 phosphorylation was shown to be concentration-dependently induced by 8-iso-PGF 2␣ . These effects were mediated via TBXA2R activation because SQ-29548 abrogated 8-iso-PGF 2␣ -induced promigratory effects and changes in HDMEC signaling transduction. Moreover, Rho kinase inhibitor Y-27632 abolished the stimulatory effect of 8-iso-PGF 2␣ on basal HDMEC migration. These results suggest that lower concentrations of 8-iso-PGF 2␣ are able to induce concerted activation of Akt and Rho kinase via activation of the TBXA2R and by this means moderately stimulate basal endothelial cell motility in the absence of VEGF (a scenario unlikely to occur in vivo because VEGF and other growth factors are constantly secreted under physiological conditions), whereas 8-iso-PGF 2␣ (and other isoprostanes tested) concentrationdependently inhibit VEGF-induced EC migration. Moreover, promigratory concentrations of 8-iso-PGF 2a did not induce basal cardiac angiogenesis in vitro. Hence, the physiological relevance of isoprostane-induced basal endothelial cell migration remains unclear.
In conclusion, our study demonstrates for the first time that isoprostanes exert an inhibitory effect on VEGF-induced migration and capillary tube formation of endothelial cells, as well as on cardiac angiogenesis in vitro and angiogenesis in vivo via activation of the TBXA2R. Taken together, our findings uncover mechanisms by which isoprostanes may exert antiangiogenic actions especially in disease states of increased oxidative stress and elevated isoprostane levels.
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